Osteosarcoma (osteogenic sarcoma)

• What is Osteosarcoma (Osteogenic sarcoma)
• Statistics on Osteosarcoma (Osteogenic sarcoma)
• Risk Factors for Osteosarcoma (Osteogenic sarcoma)
• Progression of Osteosarcoma (Osteogenic sarcoma)
• Symptoms of Osteosarcoma (Osteogenic sarcoma)
• Clinical Examination of Osteosarcoma (Osteogenic sarcoma)
• How is Osteosarcoma (Osteogenic sarcoma) Diagnosed?
• Prognosis of Osteosarcoma (Osteogenic sarcoma)
• How is Osteosarcoma (Osteogenic sarcoma) Treated?

What is Osteosarcoma (Osteogenic sarcoma)

Osteosarcoma is a type of bone cancer.

The bones of the body are a specialised form of connective tissue that form the majority of the human skeleton. They are comprised of calcium, phosphate and magnesium within a framework of type I collagen. The size of the skeleton does not tend to increase beyond puberty (when fusion of the skeletal growth plates occur) but bone is a highly metabolically active tissue undergoing constant resorption, formation and remodelling.

The Three major functions of bone can be seen as:

 

• Mechanical- support of tissues, attachment of muscles and enabling movement of the body;
• Metabolic- the bone forms the major storage reservoir for calcium and phosphate in the body; and
• Protective- bones provide the protective casing for vital internal organs and also for the bone marrow.
  

  Statistics on Osteosarcoma (Osteogenic sarcoma)

  It is is rare, accounting for less than 0.2% of new malignancies each year. However, it is the most common primary malignant bone tumour. The vast majority of bony malignancies are metastatic. More than 75% occur in patients younger than 20 years (with peaks at 10-14 for girls and 15-18 for boys) but a second smaller peak also occurs in the elderly with sex incidence being a twice as common in males.

  Geographically, the tumour is found worldwide.

  Risk Factors for Osteosarcoma (Osteogenic sarcoma)

  Genetic factors play a fundamental role in the development of osteosarcoma. Heritable mutations in the p53 germline are associated with the autosomal recessive Li Fraumeni syndrome of familial cancers and patients with mutations in the Rb gene (associated with the development of retinoblastoma) are also at a high risk of developing osteosarcoma. Osteosarcoma also arises with increased frequency in patients with osteogenesis imperfecta.

  Other predisposing factors include: Areas of rapid bone growth (as suggested by the location of tumours at sites of maximal bone growth and in regions of Paget’s disease); and radiation (especially post-radiotherapy for a solid organ tumour in childhood).

  Progression of Osteosarcoma (Osteogenic sarcoma)

  This type of tumour spreads by vascular invasion and haematogenous dissemination. Lung and distant bone metastases are the most common sites for spread.

  How is Osteosarcoma (Osteogenic sarcoma) Diagnosed?

  General investigations may show anaemia or low platelet count if bone marrow is involved. Abnormal alkaline phosphatase levels may be detected.

  Prognosis of Osteosarcoma (Osteogenic sarcoma)

  Prior to the development of chemotherapeutic techniques the prognosis from osteosarcoma was universally poor, with a 5 year survival rate of less than 20%. However, a localised osteosarcoma is now associated with a 5 year survival rate of approximately 60%.

  How is Osteosarcoma (Osteogenic sarcoma) Treated?

  Treatment for osteosarcoma revolves around surgical excision and chemotherapy. Surgery takes the form of either amputation or, in less advanced cases, limb salvage procedures where local resection is performed. Sometimes chemotherapy is used preoperatively in the hope that a non-resectable tumour requiring amputation can be shrunk and a local resection performed. The introduction of combination chemotherapy techniques and of limb sparing surgical procedures have dramatically reduced the mortality and morbidity of osteosarcoma.

  Improvement in symptoms is an important measurement. Specific monitoring may be by serial CT and radioisotope bone scanning for the detection of recurrent disease. The chest should also be monitored with serial x-rays as it may be possible to resect even multiple secondaries from an osteogenic sarcoma.

  The symptoms that may require attention are somatic pain from bone metastases, visceral pain from liver or lung metastases and neurogenic pain if nerve tissue is compressed. Coughing and breathlessness from lung involvement may require specific treatment.

  Osteosarcoma is radioresistant, and as such, radiation therapy has no role in routine management.

  (Source: David Dalley: St Vincent’s Hospital).